A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.
Dino TarabarKatia El JurdiCindy TraboulsiOlivia YvellezZoran MilenkovicStanko PetrovicBojana SuboticAnn GilsTanja BrocicIrina BrcerevicOlgica LatinovicTanja JocicDavid T RubinPublished in: Inflammatory bowel diseases (2022)
Bridging cyclosporine to vedolizumab in severe, steroid-refractory UC patients is effective and safe at inducing and maintaining clinical, endoscopic, and biochemical response and remission up to 52 weeks of follow-up. Larger prospective studies are warranted.
Keyphrases
- ulcerative colitis
- end stage renal disease
- ejection fraction
- newly diagnosed
- early onset
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- study protocol
- randomized controlled trial
- ultrasound guided
- stem cells
- systemic lupus erythematosus
- bone marrow
- drug induced
- phase ii
- preterm birth
- gestational age
- endoscopic submucosal dissection